Global Migraine Drugs Market

Description

Market Overview

The global migraine drugs market reached USD 4,035.8 million in 2022 and is projected to witness lucrative growth by reaching up to USD 9,791.1 million by 2030. The migraine drugs market is expected to exhibit a CAGR of 12.1% during the forecast period (2023-2030), owing to the increase in the preponderance of migraine globally and the increase in awareness regarding migraine and their therapy choices. Additionally, a rise in demand for secure and efficacious therapy and an increase in research and development is anticipated to promote the growth of the market.

Market Dynamics

The Treatment Advancements are Expected to Drive the Migraine Drugs Market Growth During the Forecast Period.

The treatment advancements such as the advancements in new drugs and new drug delivery systems (needle injections, nasal sprays) are expected to drive the global migraine drugs market growth during the forecast period. For example, a few of these medications can treat migraine 2-4 hours into an attack when compared to the pre-existing therapies that perform satisfactorily if administered within 30 minutes.

The Increasing Funding for Clinical Research is Providing Growth Opportunities for Migraine Drugs Market.

The growing funding to the key market players is ensuring growth opportunities for the global migraine drugs market in the upcoming years. For instance, in August 2022, Theranica, an Israel-based digital therapeutics designer concentrated on migraine care, raised around USD 45 million in Series C funding.

COVID-19 Impact Analysis

The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario along with pricing dynamics (including pricing change during and post-pandemic comparing it to pre-COVID scenarios), demand-supply spectrum (shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), government initiatives (initiatives to revive market, sector or industry by government bodies) and manufacturers strategic initiatives (what manufacturers did to mitigate the COVID issues will be covered here).

Russia-Ukraine Conflict Analysis

Ukraine and Russia are both extensive bases for international clinical trial activities. The attack on Ukraine may cause an underpowering of global drug development outcomes including drugs for migraine with the failure of prospective recruitment locations for both nations. The turmoil and disorder induced by military confrontation have a significant influence over healthcare including migraine drugs and others.

Global Recession Impact Analysis

The healthcare industry is not completely immune to recession, as healthcare institutions thought firings and employing freezes during past financial downturns. That stated, the industry does cope finer than other sectors because of its essential nature. However, the danger of recession threatens the market as inflation persists increasing. The elevated extent of tension about the persistent recession could hold a substantial influence on the scleroderma market over the following few years.

Artificial Intelligence Impact Analysis

In May 2023, Healint, a virtual clinical trial platform-delivering company, partnered with the Saitama Medical University Hospital in Japan to experiment with how AI could be employed to detect migraines. The investigation is fueled by Healint's Migraine Buddy platform for data. The research will investigate how AI could diagnose patients, pick therapies and pinpoint possible fatal circumstances positively impacting the global migraine drugs market in the upcoming years.

Segment Analysis

The global migraine drugs market is segmented based on phase, design, indication, service, and region.

The Retail Pharmacy Segment is Estimated to Hold a 35% Share of the Global Market by 2030.

The majority of migraine preventive or abortive medications are intended for relieving the induced symptoms and averting or subsiding the migraine attack. These medications are primarily analgesics and OTC medicines that are easily available from retail pharmacies. Therefore, the retail pharmacy segment is estimated to hold a dominant share of the global migraine drugs market accounting for around 35.0% of the total market throughout the forecast period.

Geographical Analysis

Europe is Estimated to Hold the Second-largest Share of the Global Migraine Drugs Market During the Forecast Period.

Europe is estimated to hold around 28.2% of the total migraine drugs market owing to the high spending on migraine by European individuals and the efforts by various organizations to spread awareness about migraine in this region. For instance, according to a new article published in September 2022, at the recent Migraine Trust International Symposium, the world's longest-established headache medical conference, supporters gathered jointly to reach for enhanced guidelines for those impacted by migraine. Migraine persists to be a considerable public health issue across Europe costing European economies an assessed €55 billion yearly in immediate and indirect health care costs.

Competitive Landscape

The major global players in the market include: Allergen, Eisai, Ltd., AstraZeneca plc, Abbott Laboratories, Eisai Co., Ltd., Endo International Plc., GlaxoSmithKline Plc., Merck & Co., Inc., Pfizer Inc., and Johnson & Johnson among others.

Why Purchase the Report?

To visualize the global migraine drugs market segmentation based on type, route of administration, distribution channel, and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of migraine drugs market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The global migraine drugs market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

Product Code: PH2530

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Type
3.2. Snippet by Route of Administration
3.3. Snippet by Distribution Channel

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Development Of Various New Cost-Effective Products
  - 4.1.1.2. Market Developments
- 4.1.2. Restraints
  - 4.1.2.1. Stringent Regulatory Authorities
- 4.1.3. Opportunity
- 4.1.4. Government Initiatives
- 4.1.5. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Forces Analysis
5.2. Regulatory Analysis
5.3. Pricing Analysis
5.4. Epidemiological Analysis
5.5. Patent Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Before COVID-19 Scenario
- 6.1.2. Present COVID-19 Scenario
- 6.1.3. Post COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers' Strategic Initiatives
6.6. Conclusion

7. Russia-Ukraine Conflict Analysis

8. Global Recession Analysis

9. Artificial Intelligence Impact Analysis

10. By Type

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.1.2. Market Attractiveness Index, By Type
10.2. Abortive Medicine
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Preventive Medicine

11. By Route of Administration

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.1.2. Market Attractiveness Index, By Route of Administration
11.2. Oral *
- 11.2.1. Introduction
- 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Injectable
11.4. Others

12. By Distribution Channel

12.1. Introduction
- 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.1.2. Market Attractiveness Index, By Distribution Channel
12.2. Hospital Based Pharmacies
- 12.2.1. Introduction
- 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Retail Pharmacies
12.4. Online Pharmacies

13. By Region

13.1. Introduction
- 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 13.1.2. Market Attractiveness Index, By Region
13.2. North America
- 13.2.1. Introduction
- 13.2.2. Key Region-Specific Dynamics
- 13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 13.2.6.1. The U.S.
  - 13.2.6.2. Canada
  - 13.2.6.3. Mexico
13.3. Europe
- 13.3.1. Introduction
- 13.3.2. Key Region-Specific Dynamics
- 13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 13.3.6.1. Germany
  - 13.3.6.2. The U.K.
  - 13.3.6.3. France
  - 13.3.6.4. Italy
  - 13.3.6.5. Spain
  - 13.3.6.6. Rest of Europe
13.4. South America
- 13.4.1. Introduction
- 13.4.2. Key Region-Specific Dynamics
- 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 13.4.6.1. Brazil
  - 13.4.6.2. Argentina
  - 13.4.6.3. Rest of South America
13.5. Asia-Pacific
- 13.5.1. Introduction
- 13.5.2. Key Region-Specific Dynamics
- 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 13.5.6.1. China
  - 13.5.6.2. India
  - 13.5.6.3. Japan
  - 13.5.6.4. Australia
  - 13.5.6.5. Rest of Asia-Pacific
13.6. Middle East and Africa
- 13.6.1. Introduction
- 13.6.2. Key Region-Specific Dynamics
- 13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

14. Competitive Landscape

14.1. Competitive Scenario
14.2. Market Share Analysis
14.3. Mergers and Acquisitions Analysis

15. Company Profiles

15.1. Abbott Laboratories
- 15.1.1. Company Overview
- 15.1.2. Type Portfolio and Description
- 15.1.3. Financial Overview
- 15.1.4. Key Developments
15.2. AbbVie Inc
15.3. Allergan Plc.
15.4. AstraZeneca PLC.
15.5. Eisai Co., Ltd.
15.6. Endo International Plc.
15.7. GlaxoSmithKline Plc.
15.8. Merck & Co., Inc.
15.9. Pfizer Inc.
15.10. Johnson & Johnson

LIST NOT EXHAUSTIVE

16. Appendix

16.1. About Us and Services
16.2. Contact Us

Global Migraine Drugs Market - 2023-2030